Brief: Karolinska Development: Positive Phase 2 Results For Eprenetapopt

Kdventures AB

22/07/2021 13:31

July 22 (Reuters) - Karolinska Development AB  KDEV.ST :
    * PORTFOLIO COMPANY APREA THERAPEUTICS ANNOUNCES POSITIVE PHASE 2 RESULTS FOR EPRENETAPOPT
    * RELAPSE FREE SURVIVAL AT 1-YEAR POST-TRANSPLANT WAS 58% AND OVERALL SURVIVAL WAS 79%.
    * OVERALL SURVIVAL (OS) AT 1-YEAR POST-TRANSPLANT WAS 79%, WITH A MEDIAN OS OF 19.3 MONTHS
    * POST-TRANSPLANT REGIMEN OF EPRENETAPOPT AND AZACITIDINE WAS WELL TOLERATED AMONG PATIENTS
IN
CLINICAL TRIAL

Source text for Eikon:  ID:nGNE75cbGv 
Further company coverage:  KDEV.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))